CGT Catapult have worked with Green Cross LabCell, a leading South Korean biopharmaceutical company, to provide regulatory advice on the company’s natural killer (NK) cell therapy product for the treatment of a range of haematological and solid tumour malignancies.
Green Cross LabCell is a subsidiary of Green Cross, and was established through the merging of Green Cross’ cell therapy and cord blood storage divisions. The company’s goal is to develop cell immunotherapies based on NK cells and treatments for intractable diseases using stem cells.
CGT Catapult has a wealth of experience in clinical feasibility in a range of clinical indications including the field of novel immunotherapy modalities in haematological and solid tumours. The CGT Catapult clinical operations team used this experience alongside their network of feasibility and clinical specialists throughout the UK healthcare system to investigate the clinical feasibility of the Green Cross LabCell’s NK cell product for clinical trials, within the UK.
This project is the first between CGT Catapult and South Korea, which is a growing market for the commercialisation of cell therapies. South Korea have approved 16 advanced therapies, and with 43 on-going research projects on advanced therapies. The South Korean Government is committed to developing cell therapies and provide funds directly linked to progress milestones. Several companies in the region are developing CAR-T and genetically engineered NK platform technologies and CAR-T and genetically engineered NK cell therapies, including Green Cross who have a preclinical genetically engineered NK cell therapy targeting a range of conventional cancers caused by solid tumours.